Invention Application
- Patent Title: CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B][1,3]OXAZEPINE-10-CARBOXAMIDE
-
Application No.: US15588346Application Date: 2017-05-05
-
Publication No.: US20170333438A1Publication Date: 2017-11-23
- Inventor: Ernest A. Carra , Irene Chen , Katie Ann Keaton , Scott E. Lazerwith , Vahid Zia
- Applicant: Gilead Sciences, Inc.
- Main IPC: A61K31/5365
- IPC: A61K31/5365 ; A61K9/20 ; A61K45/06 ; C07D498/18 ; C07D498/14 ; A61K31/537
![CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B][1,3]OXAZEPINE-10-CARBOXAMIDE](/abs-image/US/2017/11/23/US20170333438A1/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
Public/Granted literature
Information query